Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript
Emergent BioSolutions reported Q1 2026 revenue of $156 million, exceeding guidance, with an adjusted EBITDA of $36 million, driven by strong MCM performance and strategic international diversification. The company reduced its net debt by 22% in 2025 and aims for further improvement, while expanding its MCM business and pursuing accretive external opportunities, including a manufacturing partnership with SAB Biotherapeutics. Emergent also highlighted its continued leadership in the Narcan market and efforts to expand access and awareness for overdose prevention.
APR 14·Bioscience Association Manitoba▲
Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness
Emergent BioSolutions is expanding access to NARCAN® Nasal Spray by launching a new carrying case and multipack options, alongside a college campus outreach program. These initiatives aim to increase preparedness for opioid overdoses and reduce associated stigma, particularly among young adults. The company partnered with Pro Football Hall of Famer Emmitt Smith and Release Recovery Founder/CEO Zac Clark for an engagement at Southern Methodist University to promote awareness and education.
MAR 26·Stock Titan▲
U.S. and foreign governments order $60M in smallpox countermeasures
Emergent BioSolutions (NYSE: EBS) has secured over $60 million in new orders for smallpox medical countermeasures. This includes a $54 million contract option with the U.S. government for CNJ-016 (VIGIV) and $6.6 million in orders from an international government partner for ACAM2000. Additionally, the company referenced multi-year agreements with Canada valued up to $140 million CAD, with more than $35 million CAD expected in 2026.
